On the CMS SNF Open Door Forum on March 2nd, a caller asked if the antipsychotics quality measures could be re-evaluated to expand the list of exempting diagnoses. Currently, only residents diagnosed with schizophrenia, Huntington’s disease, and Tourette’s syndrome are exempted from the short- and long-stay measures. LeadingAge has advocated to CMS for re-evaluation of these measures, most recently in response to the schizophrenia audits announced publicly in January 2023. In response to the caller question, a representative from CMS confirmed that CMS is currently re-evaluating the antipsychotic quality measures and a Technical Expert Panel was held recently on the topic. No further details are available at this time.
